AI Identifies Cause of Alzheimer’s Disease and Finds Potential Treatment in Breakthrough Study

Researchers at UC San Diego have identified that the PHGDH gene plays a causal role in spontaneous Alzheimer’s disease through a previously unknown secondary function affecting cellular gene regulation. Utilizing artificial intelligence, they discovered this mechanism and subsequently found that NCT-503, a small molecule, effectively targets this pathway. Testing in mouse models demonstrated significant alleviation of Alzheimer’s progression, highlighting the potential for a new therapeutic approach. The next steps involve optimizing NCT-503 and advancing it through regulatory studies toward clinical trials.

Recent research has uncovered a novel role for phosphoglycerate dehydrogenase (PHGDH) in Alzheimer’s disease, offering new hope for potential therapeutic interventions. Traditionally known as an enzyme central to serine metabolism, PHGDH has now been identified as a regulator of gene expression linked to amyloid pathology.

The Discovery of PHGDH’s Dual Role

Using advanced AI-driven analysis, researchers discovered that PHGDH can bind DNA and influence the expression of genes associated with amyloid plaques. This dual role suggests that targeting PHGDH could offer a new approach to combating Alzheimer’s disease without disrupting serine production, which is critical for brain function.

The Development of NCT-503

To exploit this discovery, scientists developed NCT-503, a small molecule inhibitor designed to target PHGDH’s regulatory function. Testing in mouse models with genetic mutations linked to Alzheimer’s demonstrated promising results: NCT-503 reduced disease progression and improved cognitive functions such as memory and anxiety levels.

Limitations of the Study

While these findings are encouraging, it is important to note that the study was conducted using transgenic mice. These models may not fully replicate sporadic Alzheimer’s cases in humans, highlighting the need for further research in human models.

Next Steps for Clinical Development

The next phase involves optimizing NCT-503 for clinical trials to evaluate its safety and efficacy in human subjects. If successful, this approach could offer a novel therapeutic strategy aimed at preventing amyloid plaque formation upstream. The potential for oral administration of such compounds would also enhance patient compliance compared to current infusion-based treatments.

Future Directions

Understanding PHGDH’s role as a transcription factor could provide deeper insights into its functions and therapeutic potential in neurodegenerative diseases. Further studies are essential to validate these findings in human models and ensure that any resulting therapies are both safe and effective.